Fig. S12


a
KRAS mutation (biallelic)
Enrichment score
permutated p=0.026
max(ES) = 11.96
Decreased CD8+ T cell
Increased CD8+ T cell
Primary tumors
(Order by CD8+ T cell score by CIBERSORT)
p=0.034
CD8+ T cell score (Cibersort)
Biallelic
Monoallelic
Wild
KRAS mutation
b
Tumors with KRAS mutation
p=0.029
Monoallelic (97%)
Biallelic (3%)
Biallelic (26%)
Monoallelic (74%)
Immunogenic
Non-immunogenic
c
KRAS status
T cells CD8 (CIBERSORT)
T cell (MCPcounter)
Wnt pathway GSVA
KRAS exp (log2)
TIM class
Bi
Mono
WT
Active
Exhausted
Desert
d
Non-immunogenic
Biallelic mutation
KRAS (NM_033360)
G12D/C
G13C
Q61R
A146T
H_N_K_Ras_like COG1100
192 aa
Q22K
G13D
G12V/S/D
Missense mutation
I187V
Monoallelic mutation
Immunogenic
Biallelic mutation
KRAS (NM_033360)
A146T
H_N_K_Ras_like COG1100
192 aa
V14I
G13D
Q61H
A146T
Missense mutation
I187V
G12D/V/S
Monoallelic mutation
e
Organoids (cancer cells)
Cytokines (cancer tissues)
p=0.014
p=0.019
p=0.015
CXCL3
PDL1
Granzyme B
Biallelic
Monoallelic
Wild
KRAS mutation
Immune cells (microenvironment)
ns
ns
p=0.018
ns
Total immune score
CD8 T/Total immune ratio
M2 Mcrophage/Total immune ratio
Neutrophil/Total immune ratio
TIM feature (primary tissue)
Total immune score
CD8+ T cell
Neutrophil
M2 macrophage
PDL1
CXCL3
Cancer cell feature (organoid)
KRAS mut+ (biallelic)
KRAS wild type